Typically dosages for dementia are 1 mg. daily, maximum 2 mg. daily, although persons using it for preventative measures may want to consider 0.25 mg. to 0.5 mg. (dependant upon need). It is known that at dosages greater than 2 mg. daily Agilect can also become a MAO-A inhibitor and therefore will interfere more readily with other drugs such as SSRI anti-depressants etc. Unless under the guidance of a health professional, the concurrent use of any other MAO inhibiting products, such as Deprenyl, Gerovital, St. John’s Wort, as well as other anti-depressants, particularly SSRI’s such as Paxil and Prozac etc., should be avoided.
The effect of a long-term regimen of Agilect on human lifespan is unknown, yet since Deprenyl has increased both life-expectancy and maximum lifespan in animal studies, it is possible, and that Agilect’s metabolic profile may have similar advantages for antiaging. For those with Parkinson’s disease, particularly who are undergoing a multi-approach therapy, Agilect may well be the drug of choice.
Persons taking prescription medication and pregnant or lactating women should consult a physician before using this product. Long-term use of this product should be supervised and monitored by a health care professional.
This product and its statements have not been evaluated by the FDA. This product is not intended to treat, cure or prevent any disease. The above information is provided under the supplying company's terms and conditions and should not replace the advice of your personal physician.
This product is not available for shipment to the EU